Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,322
datasets available to search
ShareScore release 0.9.0
Dataset results
2,322 results for “Circulation”
Alterations in circulating monocytes predict COVID-19 severity and include chromatin modifications still detectable six months after recovery
GEO Series GSE180594. Homo sapiens. 33 samples. Type: Expression profiling by array.
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes
GEO Series GSE241673. Homo sapiens. 67 samples. Type: Methylation profiling by high throughput sequencing.
raw data related to project "Circulating biomarkers as predictors of gender-specific response to Immune Checkpoint Inhibitors in melanoma and non-small-cell lung cancer patients"
<p><strong>Sex-related differences in serum biomarker levels predict the activity and efficacy of Immune Checkpoint Inhibitors in advanced melanoma and Non-Small Cell Lung Cancer patients.</strong></p> <p><strong>Abstract </strong></p> <p><strong>Background:</strong> Immune Checkpoint Inhibitors (ICIs) lead to durable response and a significant increase in long-term survival in patients with advanced malignant melanoma (MM) and Non-Small Cell Lung Cancer (NSCLC). The identification of serum cytokines that can predict their activity and efficacy, and their sex interaction, could improve treatment personalization. </p> <p><strong>Methods: </strong>In this prospective study, we enrolled immunotherapy-naïve patients affected by advanced MM and NSCLC treated with ICIs. The primary endpoint was to dissect the potential sex correlations between serum cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, GM-CSF, MCP-1, TNF-ɑ, IP-10, VEGF, sPD-L1) and the overall response rate (ORR). Secondly, we analyzed biomarker changes during treatment related to ORR, disease control rate (DCR), progression free survival (PFS) and overall survival (OS). Blood samples, collected at baseline and during treatment until disease progression (PD) or up to 2 years, were analyzed using Luminex xMAP or ELLA based technology. </p> <p>Three Luminex xMAP assays and two ELLA microfluidic cartridges were used to screen 28 immune-related biomarkers in 38 paired serum and citrate-theophylline-adenosine-dipyridamole (CTAD) plasma samples collected from 10 advanced melanoma or non-small cell lung cancer (NSCLC) patients at different time points during immunotherapy.</p> <p><strong>Results</strong>: Serum samples from 161 patients (98 males/63 females; 92 MM/69 NSCLC) were analyzed for treatment response. At baseline, IL-6 was significantly lower in females (F) <em>versus</em> males (M); lower levels of IL-4 in F and of IL-6 in both sexes significantly correlated with a better ORR, while higher IL-4 and TNF-ɑ values were predictive of a lower probability of ORR in F <em>versus</em> M. One hundred and sixty-five patients were evaluable for survival analysis: at multiple Cox regression, an increased risk of PD was observed in F with higher baseline values of IL-4, sPD-L1 and IL-10, while higher IL-6 was a negative predictor in males. In males, higher levels of GM-CSF predict a longer survival, whereas higher IL-1β predicts a shorter survival. Regardless of sex, high baseline IL-8 values were associated with an increased risk of both PD and death, and high IL-6 levels only with shorter OS. </p> <p>Twenty-three of 28 biomarkers were detected both in serum and plasma by at least one of the assays, including IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, GM-CSF, IFN-γ, TNF-α, VEGF, IP-10, MCP-1, eotaxin, fractalkine, G-CSF, IFN-α, IL-1RA, IL-13, IL-17A, MIP-1β and sPD-L1. Conversely, FGF-2 and IL-1α were not detected in both matrices; GRO-α factor and EGF were detected only in serum and MIP-1α only in plasma. sPD-L1, MCP-1, IFN-γ, IL-8, MIP-1β and VEGF were, respectively, 1.15-, 1.44-, 1.83-, 2.43-, 2.82-, 6.72-fold higher in serum, whereas IL-10, IL-4, IL-2 and IL-5 were 1.05-, 1.19-, 1.92- and 2.17-fold higher, respectively, in plasma. IP-10 levels were higher in plasma but, as well as for VEGF, the bias serum versus plasma varied depending on the assay used (IP-10: −5.7% to −145%; VEGF: 115% to 165%). No significant differences were found for the remaining nine analyzed cytokines.</p> <p><strong>Conclusions</strong></p> <p>Serum IL-1β, IL-4, IL-6, IL-10, GM-CSF, TNFɑ, and sPDL1 had a significant independent sex-related predictive impact on ORR, PFS and OS in melanoma and NSCLC patients treated with ICIs. These results will potentially pave the way for new ICI combinations, designed according to baseline and early changes of these cytokines and stratified by sex. </p> <p>The cytokine and sPD-L1 levels may differ between serum and plasma samples collected from cancer patients treated with immunotherapy, and the results obtained can be influenced by the different characteristics of the tested assays.</p>
Dataset related to the article "Circulating mircoRNAs linked to inflammatory pathways are altered in subject with aortic valve sclerosis"
<p><span>Plasma miRNA profiling performed by HTG EdgeSeq miRNA whole transcriptome assay in subjects with and without aortic valve sclerosis (AVSc).</span></p>
Dataset related to article "Circulating and synovial Pentraxin-3 (PTX3) expression levels correlate with rheumatoid arthritis severity and tissue infiltration indepndently of comventional treatements response."
<p>This record contains raw data related to article “Circulating and synovial Pentraxin-3 (PTX3) expression levels correlate with rheumatoid arthritis severity and tissue infiltration indepndently of comventional treatements response."</p> <p><strong>Aims: </strong>To determine the relationship between PTX3 systemic and synovial levels and the clinical features of rheumatoid arthritis (RA) in a cohort of early, treatment naïve patients and to explore the relevance of PTX3 expression in predicting response to conventional-synthetic (cs) Disease-Modifying-Anti-Rheumatic-Drugs (DMARDs) treatment.</p> <p><strong>Methods: </strong>PTX3 expression was analyzed in 119 baseline serum samples from early naïve RA patients, 95 paired samples obtained 6-months following the initiation of cs-DMARDs treatment and 43 healthy donors. RNA-sequencing analysis and immunohistochemistry for PTX3 were performed on a subpopulation of 79 and 58 synovial samples, respectively, to assess PTX3 gene and protein expression. Immunofluorescence staining was performed to characterize PTX3 expressing cells within the synovium.</p> <p><strong>Results: </strong>Circulating levels of PTX3 were significantly higher in early RA compared to healthy donors and correlated with disease activity at baseline and with the degree of structural damages at 12-months. Six-months after commencing cs-DMARDs, a high level of PTX3, proportional to the baseline value, was still detectable in the serum of patients, regardless of their response status. RNA-seq analysis confirmed that synovial transcript levels of PTX3 correlated with disease activity and the presence of mediators of inflammation, tissue remodeling and bone destruction at baseline. PTX3 expression in the synovium was strongly linked to the degree of immune cell infiltration, the presence of ectopic lymphoid structures and seropositivity for autoantibodies. Accordingly, PTX3 was found to be expressed by numerous synovial cell types such as plasma cells, fibroblasts, vascular and lymphatic endothelial cells, macrophages, and neutrophils. The percentage of PTX3-positive synovial cells, although significantly reduced at 6-months post-treatment as a result of global decreased cellularity, was similar in cs-DMARDs responders and non-responders.</p> <p><strong>Conclusion: </strong>This study demonstrates that, early in the disease and prior to treatment modification, the level of circulating PTX3 is a reliable marker of RA activity and predicts a high degree of structural damages at 12-months. In the joint, PTX3 associates with immune cell infiltration and the presence of ectopic lymphoid structures. High synovial and peripheral blood levels of PTX3 are associated with chronic inflammation characteristic of RA. Additional studies to determine the mechanistic link are required.</p>
Diabetic peripheral neuropathy is associated with changes in the frequency and function of circulating Natural Killer cells: results of a pilot study in patients with diabetic foot.
<p><strong><span>Background: </span></strong><span>Diabetic critical limb-threatening ischemia (CLTI) is a severe vascular disease with a high incidence of amputation and death. Circulating inflammatory markers may represent early diagnostic and prognostic tools. We previously showed that patients with diabetes mellitus and CLTI bear low abundance and impaired functionality of pro-angiogenic CD34<sup>+</sup> hematopoietic stem and progenitor cells (HSPCs) and high frequency of natural killer cells (NKs). However, no study assessed the frequency, phenotype, and function of NKs in the early stage of CLTI characterized by neuropathy.<strong> Methods: </strong>We enrolled 177 subjects sorted into 5 groups reflecting CLTI progression: 1) non-diabetic healthy controls (n=25), diabetic patients 2) without neurovascular complications (n=27), 3) with peripheral neuropathy (n=39), 4) with peripheral neuropathy and foot lesions (n=42), 5) with peripheral neuroischemia and foot lesions (n=44). We assessed the frequency of circulating B-, CD4<sup>+,</sup> and CD8<sup>+</sup> T-cells, NKs, and CD34<sup>+</sup>HSPCs, by a flow cytometry (FC)-based diagnostic kit. We investigated by FC the frequency of circulating NK subpopulations in donors with diabetic neuropathy (n=16) and controls (n=16). We characterized FACS-sorted circulating NKs secretome by antibody membrane arrays and we tested its pro-angiogenic potential<em> in vitro</em> and <em>in vivo</em> in <em>Hirudo verbana</em>.<strong> Results: </strong>Using age and sex-adjusted logistic multivariate models, we observed a decrease in CD34<sup>+</sup>HSPCs in all diabetic groups compared to control. Interestingly, NK frequency was increased in diabetic patients with neuropathy. Although the frequency of angiogenic NKs was similar in all groups, functionally, NKs from patients with diabetic neuropathy showed impaired degranulation <em>in vitro</em>, and reduced angiogenic ability <em>in vitro </em>and <em>in vivo</em>. Neuropathic NKs showed downregulation of angiogenic factors (IL-8, PDGF-B) and upregulation of factors related to monocyte/macrophage migration, effectively recruiting macrophages <em>in vivo</em>.<strong> Conclusion:</strong> By a routine laboratory test, we identified a specific cellular signature for patients with diabetes mellitus and peripheral neuropathy that includes low CD34<sup>+</sup>HSPCs and high NK frequency. Moreover, we show for the first time a functional impairment of NKs in neuropathic patients. If confirmed in larger cohorts, FACS detection of the circulating anti-angiogenic NK cell populations could be used for the early diagnosis of diabetic CLTI, a still unmet clinical need.</span></p>
Transposon DNA sequences facilitate the tissue-specific horizontal transfer of circulating tumor DNA between human cells
<p>The uploaded files are in the fasta format and are outputs from de novo assembly using the SGA algorithm (https://github.com/jts/sga). The description of the files are as below:</p> <table> <tbody> <tr> <td><strong>Filename</strong></td> <td><strong>description</strong></td> </tr> <tr> <td>772.final.fa</td> <td>Multiple Myeloma ctDNA</td> </tr> <tr> <td>54128-4M7.final.fa</td> <td>Pancreatic cancer cells coculture with multiple myeloma ctDNA</td> </tr> <tr> <td>54128-6MP.final.fa</td> <td>Multiple myeloma cells coculture with pancreatic cancer ctDNA</td> </tr> <tr> <td>MIA-Cells.final.fa</td> <td>Pancreatic cancer cells</td> </tr> <tr> <td>MIA-cells-with-P201812-2.final.fa</td> <td>Pancreatic cancer cells coculture with pancreatic cancer ctDNA</td> </tr> <tr> <td>MM1S-cells.final.fa</td> <td>Multiple Myeloma cells</td> </tr> <tr> <td>MM1S-cells-with-772-2.final.fa</td> <td>Mutiple myeloma cells coculture with Multiple myeloma ctDNA</td> </tr> <tr> <td>P201812-2.final.fa</td> <td>Pancreatic Cancer ctDNA</td> </tr> </tbody> </table>
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
ClinicalTrials.gov study NCT05757843. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions
ClinicalTrials.gov study NCT06649838. IPD Sharing: Not stated. Countries: 0. Publications: 0.
The Establishment and Clinical Application of a Prediction Model of Lung Cancer Distant Metastasis Based on the Genomic Characteristics of Circulating Tumor Cells
ClinicalTrials.gov study NCT04568720. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Circulating Innate Lymphoid Cell Type 2 (ILC2) Levels and Asthma: a Case-control Study
ClinicalTrials.gov study NCT03128762. IPD Sharing: Not stated. Countries: 0. Publications: 0.
OPTImisation and Standardization of CIRCulating Cell-free DNA Ex-traction Protocols in a Diagnostic Setting
ClinicalTrials.gov study NCT06869070. IPD Sharing: Not stated. Countries: 0. Publications: 0.
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML
ClinicalTrials.gov study NCT03138395. IPD Sharing: NO. Countries: 0. Publications: 0.
Descriptive Study of Circulating Gene or Protein Inflammatory Biomarkers and Bioimpedance Parameters in a Population of Patients Hospitalized for Decompensated Heart Failure With Preserved or Mildly R
ClinicalTrials.gov study NCT07320014. IPD Sharing: NO. Countries: 0. Publications: 0.
Impact of Protamine Dose Reduction on Platelet Aggregation After Extracorporeal Circulation for Minimally Invasive Aortic Valve Replacement Surgery
ClinicalTrials.gov study NCT06254404. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Circulating Factors in Nephrotic Syndrome
ClinicalTrials.gov study NCT06315504. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Short Term Dietary Serine Supplementation and Circulating Serine Levels
ClinicalTrials.gov study NCT02528994. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis
ClinicalTrials.gov study NCT02756546. IPD Sharing: YES. Countries: 0. Publications: 0.
Quantification of Thrombocytes Number and Function in Patients Undergoing Prolonged Extracorporeal Circulation
ClinicalTrials.gov study NCT02771223. IPD Sharing: NO. Countries: 0. Publications: 0.
Adherence to the Mediterranean Diet and Circulating Levels of Sirtuin 4 in Obese Subjects
ClinicalTrials.gov study NCT02840981. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.